Literature DB >> 28464209

Alanine scan of the opioid peptide dynorphin B amide.

Anand A Joshi1, Thomas F Murray2, Jane V Aldrich1,3.   

Abstract

To date structure-activity relationship (SAR) studies of the dynorphins (Dyn), endogenous peptides for kappa opioid receptors (KOR), have focused almost exclusively on Dyn A with minimal studies on Dyn B. While both Dyn A and Dyn B have identical N-terminal sequences, their C-terminal sequences differ, which could result in differences in pharmacological activity. We performed an alanine scan of the non-glycine residues up through residue 11 of Dyn B amide to explore the roles of these side chains in the activity of Dyn B. The analogs were synthesized by fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide synthesis and evaluated for their opioid receptor affinities and opioid potency and efficacy at KOR. Similar to Dyn A the N-terminal Tyr1 and Phe4 residues of Dyn B amide are critical for opioid receptor affinity and KOR agonist potency. The basic residues Arg6 and Arg7 contribute to the KOR affinity and agonist potency of Dyn B amide, while Lys10 contributes to the opioid receptor affinity, but not KOR agonist potency, of this peptide. Comparison to the Ala analogs of Dyn A (1-13) suggests that the basic residues in the C-terminus of both peptides contribute to KOR binding, but differences in their relative positions may contribute to the different pharmacological profiles of Dyn A and Dyn B. The other unique C-terminal residues in Dyn B amide also appear to influence the relative affinity of this peptide for KOR versus mu and delta opioid receptors. This SAR information may be applied in the design of new Dyn B analogs that could be useful pharmacological tools.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-terminal basic residues; alanine scan; dynorphin B; kappa opioid receptor; structure-activity relationships

Mesh:

Substances:

Year:  2017        PMID: 28464209      PMCID: PMC6003702          DOI: 10.1002/bip.23026

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  46 in total

1.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Hypothermia elicited by some prodynorphin-derived peptides: opioid and non-opioid actions.

Authors:  E Cavicchini; S Candeletti; S Spampinato; S Ferri
Journal:  Neuropeptides       Date:  1989-07       Impact factor: 3.286

3.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

4.  Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms.

Authors:  K Tan-No; G Cebers; T Yakovleva; B Hoon Goh; I Gileva; K Reznikov; M Aguilar-Santelises; K F Hauser; L Terenius; G Bakalkin
Journal:  Exp Cell Res       Date:  2001-09-10       Impact factor: 3.905

5.  Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone.

Authors:  T W Vanderah; T Laughlin; J M Lashbrook; M L Nichols; G L Wilcox; M H Ossipov; T P Malan; F Porreca
Journal:  Pain       Date:  1996-12       Impact factor: 6.961

6.  Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.

Authors:  S Arttamangkul; J E Ishmael; T F Murray; D K Grandy; G E DeLander; B L Kieffer; J V Aldrich
Journal:  J Med Chem       Date:  1997-04-11       Impact factor: 7.446

7.  Opioid receptor selectivity of dynorphin gene products.

Authors:  I F James; W Fischli; A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.

Authors:  Wei-Jie Fang; Yanjun Cui; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

9.  Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism.

Authors:  Koichi Tan-No; Akihisa Esashi; Osamu Nakagawasai; Fukie Niijima; Takeshi Tadano; Chikai Sakurada; Tsukasa Sakurada; Georgy Bakalkin; Lars Terenius; Kensuke Kisara
Journal:  Brain Res       Date:  2002-10-11       Impact factor: 3.252

10.  Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.

Authors:  Peter W Schiller; Grazyna Weltrowska; Thi M-D Nguyen; Carole Lemieux; Nga N Chung; Yixin Lu
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

View more
  1 in total

1.  Dynorphin-based "release on demand" gene therapy for drug-resistant temporal lobe epilepsy.

Authors:  Alexandra S Agostinho; Mario Mietzsch; Luca Zangrandi; Iwona Kmiec; Anna Mutti; Larissa Kraus; Pawel Fidzinski; Ulf C Schneider; Martin Holtkamp; Regine Heilbronn; Christoph Schwarzer
Journal:  EMBO Mol Med       Date:  2019-09-05       Impact factor: 12.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.